Health Trials

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

ConditionsNon Small Cell Lung CancerEGFR Gene MutationALK Gene MutationROS1 Gene MutationMET Gene Mutation
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital

About this trial

The purpose of this study is to assess the Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation.

Eligibility criteria

Qualifiers

Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.

Age ≥ 18 years.

Histologically or cytologically confirmed, Stage IV NSCLC.

Oncogenic mutations confirmed by an accredited local laboratory, including EGFR, ALK, ROS1 etc.

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Osimertinib
  • Alectinib 150 MG
  • Crizotinib 250 MG
  • Savolitinib, Crizotinib.
  • Chemotherapy

Treatment groups

6,000 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Sponsors and collaborators

Hunan Province Tumor Hospital

Lead sponsor

Source ClinicalTrials.gov